Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24884910 | 0.82 | SMN1; SMN2 (0.35) | SMN1; SMN2CRBN | |
| SCHEMBL21937436 | 0.81 | SMN1; SMN2 (0.34) | SMN1; SMN2CRBN | |
| SCHEMBL18185800 | 0.79 | SMN1; SMN2 (0.48) | FFAR3SMN1; SMN2 | |
| SCHEMBL9312163 | 0.75 | BRD4 (0.49) | SMN1; SMN2CRBN | |
| SCHEMBL18821254 | 0.75 | CRBN (0.31) | SMN1; SMN2CRBN | |
| SCHEMBL24360491 | 0.72 | CRBN (0.33) | CRBN | |
| SCHEMBL249184 | 0.72 | — | — | |
| SCHEMBL2311457 | 0.72 | FFAR3 (0.62) | FFAR3 | |
| SCHEMBL3519272 | 0.68 | FFAR3 (0.50) | FFAR3 | |
| SCHEMBL16932247 | 0.68 | SMN1; SMN2 (0.33) | SMN1; SMN2CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4631573-A2 | TEAD INHIBITORS | Orion Corporation (FI) | 2025-10-15 | — | — | EP | disclosed |
| EP-4323338-B1 | TEAD INHIBITORS | ORION CORP (FI) | 2025-10-08 | — | — | EP | disclosed |
| US-20230014907-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-01-19 | — | — | US | disclosed |
| US-20230011118-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-01-12 | — | — | US | disclosed |
| WO-2021252859-A1 | INHIBITORS OF APOL1 AND USE OF THE SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-12-16 | — | — | WO | disclosed |
| WO-2021252849-A1 | INHIBITORS OF APOL1 AND USE OF THE SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-12-16 | — | — | WO | disclosed |
| US-20180022747-A1 | Factor IXa Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022747-A1 | Factor IXa Inhibitors | F9, TFPI, F12 | FFAR3 597/4885SMN1; SMN2 3089/4885CRBN 2486/4885 |
| US-20230014907-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, APOB, NPC1L1 | FFAR3 2528/4885SMN1; SMN2 2619/4885CRBN 2852/4885 |
| US-20230011118-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, APOB, SAAL1 | FFAR3 2516/4885SMN1; SMN2 2720/4885CRBN 1655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.